JACQUES KESSL

Dr. JACQUES KESSL

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PPPratiq A. Patel
Pratiq A. Patel
NKNina Kvaratskhelia
Nina Kvaratskhelia
YMYara Mansour
Yara Mansour
JAJanet Antwi
Janet Antwi
LFLei Feng
Lei Feng
JFJames R. Fuchs
James R. Fuchs

14 September 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NJNicholas G. Jentsch
Nicholas G. Jentsch
AHAlison P. Hart
Alison P. Hart
JHJared D. Hume
Jared D. Hume
JSJian Sun
Jian Sun
KMKaitlin A. McNeely
Kaitlin A. McNeely
JKJACQUES KESSL
JACQUES KESSL

28 September 2018 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
NJNicholas G. Jentsch
Nicholas G. Jentsch
JHJared D. Hume
Jared D. Hume
ECEmily B. Crull
Emily B. Crull
SBSamer M. Beauti
Samer M. Beauti
APAmy H. Pham
Amy H. Pham
MDMatthew Donahue
Matthew Donahue
A convenient two-step synthesis of ethyl 4-hydroxy-2-methylquinoline-3-carboxylate derivatives has been developed starting from commercially available 2-aminobenzoic acids. In step 1, the anthranilic acids are smoothly converted to isatoic anhydrides using solid triphosgene in THF. In step 2, the anhydride electrophiles are reacted with the sodium enolate of ethyl acetoacetate, generated from sodium hydroxide, in warm N,N-dimethylacetamide resulting in the formation of substituted quinolines. A degradation–build-up strategy of the ethyl ester at the 3-position allowed for the construction of the α-hydroxyacetic acid residue required for the synthesis of key arylquinolines involved in an HIV integrase project.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JSJian Sun
Jian Sun
KPKrunal Hiteshkumar Patel
Krunal Hiteshkumar Patel
JHJared Hume
Jared Hume
Julie A. PigzaJulie A. Pigza
Julie A. Pigza
MDMatthew Donahue
Matthew Donahue
JKJACQUES KESSL
JACQUES KESSL
During the integration step, HIV-1 integrase (IN) interacts with viral DNA and the cellular cofactor LEDGF/p75 to effectively integrate the reverse transcript into the host chromatin. Allosteric HIV-1 integrase inhibitors (ALLINIs) are a new class of antiviral agents that bind at the dimer interface of the IN catalytic core domain and occupy the binding site of LEDGF/p75. While originally designed to block IN-LEDGF/p75 interactions during viral integration, several of these compounds have been shown to also severely impact viral maturation through an IN multimerization mechanism. In this study, we tested the hypothesis that these dual properties of ALLINIs could be decoupled toward late stage viral replication effects by generating additional contact points between the bound ALLINI and a third subunit of IN. By sequential derivatization at position 7 of a quinoline-based ALLINI scaffold, we show that IN multimerization properties are enhanced by optimizing hydrophobic interactions between the compound and the C-terminal domain of the third IN subunit. These features not only improve the overall anti-viral potencies of these compounds but also significantly shift the ALLINIs selectivity toward the viral maturation stage. Thus, we demonstrate that in order to fully maximize the potency of ALLINIs, the interactions between the inhibitor and all three IN subunits need to be simultaneously optimized.

28 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
JSJian Sun
Jian Sun
JKJACQUES KESSL
JACQUES KESSL
Allosteric HIV-1 Integrase (IN) Inhibitors or ALLINIs bind at the dimer interface of the IN, away from the enzymatic catalytic site, and disable viral replication by inducing over-multimerization of IN. Interestingly, these inhibitors are capable of impacting both the early and late stages of viral replication. To better understand the important binding features of multi-substituted quinoline-based ALLINIs, we have surveyed published studies on IN multimerization and antiviral properties of various substituted quinolines at the 4, 6, 7, and 8 positions. Here we show how the efficacy of these inhibitors can be modulated by the nature of the substitutions at those positions. These features not only improve the overall antiviral potencies of these compounds but also significantly shift the selectivity toward the viral maturation stage. Thus, to fully maximize the potency of ALLINIs, the interactions between the inhibitor and multiple IN subunits need to be simultaneously optimized.

2 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LDLong Phi Dinh
Long Phi Dinh
JSJian Sun
Jian Sun
CGCourtney Glenn
Courtney Glenn
KPKrunal Hiteshkumar Patel
Krunal Hiteshkumar Patel
Julie A. PigzaJulie A. Pigza
Julie A. Pigza
JKJACQUES KESSL
JACQUES KESSL
Allosteric HIV-1 integrase (IN) inhibitors, or ALLINIs, are a new class of antiviral agents that bind at the dimer interface of the IN, away from the enzymatic catalytic site and block viral replication by triggering an aberrant multimerization of the viral enzyme. To further our understanding of the important binding features of multi-substituted quinoline-based ALLINIs, we have examined the IN multimerization and antiviral properties of substitution patterns at the 6 or 8 position. We found that the binding properties of these ALLINIs are negatively impacted by the presence of bulky substitutions at these positions. In addition, we have observed that the addition of bromine at either the 6 (6-bromo) or 8 (8-bromo) position conferred better antiviral properties. Finally, we found a significant loss of potency with the 6-bromo when tested with the ALLINI-resistant IN A128T mutant virus, while the 8-bromo analog retained full effectiveness.